Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Zhejiang Hisun Pharmaceutical Co FCF Margin %?
Zhejiang Hisun Pharmaceutical CoSHSE:600267 -1.18%58 FCF Margin % is 13.52% as of Mar. 2026, which is 52% above its 10-year median of 8.87. GuruFocus rates SHSE:600267 with a GF Score™ of 58/100 and a GF Value™ of ¥8.85 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 963 Drug Manufacturers companies, Zhejiang Hisun Pharmaceutical Co ranks better than 85.25% on this metric.
The historical rank and industry rank for Zhejiang Hisun Pharmaceutical Co's FCF Margin % or its related term are showing as below:
SHSE:600267'
s FCF Margin % Range Over the Past 10 Years
Min: -10.18 Med: 8.87 Max: 18.82
Current: 17.12
During the past 13 years, the highest FCF Margin % of Zhejiang Hisun Pharmaceutical Co was 18.82%. The lowest was -10.18%. And the median was 8.87%.
SHSE:600267's FCF Margin % is ranked better than 85.25% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.57
vs SHSE:600267: 17.12
Zhejiang Hisun Pharmaceutical Co FCF Margin % Related Terms
Zhejiang Hisun Pharmaceutical Co FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co FCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Hisun Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Hisun Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Hisun Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Hisun Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) has a FCF Margin % of 13.52% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. This is 52% above median its historical median of 8.87. According to the industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #142 out of 963 companies in the Drug Manufacturers industry, placing it in the top 14.7%.
Is Zhejiang Hisun Pharmaceutical Co's FCF Margin % too high?
Zhejiang Hisun Pharmaceutical Co's current FCF Margin % of 13.52% is 52% above median its 10-year median of 8.87. The Drug Manufacturers industry median FCF Margin % is 2.57. Zhejiang Hisun Pharmaceutical Co's value of 13.52% is 426.1% above this industry median. Based on the distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #142 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Hisun Pharmaceutical Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Pharmaceutical Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #142 out of 963 companies for FCF Margin %. This places Zhejiang Hisun Pharmaceutical Co in the top 15% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.57. Zhejiang Hisun Pharmaceutical Co's value of 13.52% is 426.1% above this benchmark. While the company's 10-year median is 8.87 vs. the industry median of 2.57, Zhejiang Hisun Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Hisun Pharmaceutical Co's current FCF Margin % of 13.52% is 426.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Hisun Pharmaceutical Co's current FCF Margin % is 13.52%, which is 52% above median its own 10-year median of 8.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co (SHSE:600267) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.85, compared to a current price of ¥11.72 — trading 32.4% above its estimated fair value. The current FCF Margin % is 13.52%, which is 52% above median its 10-year median of 8.87 and 426.1% above the Drug Manufacturers industry median of 2.57. Zhejiang Hisun Pharmaceutical Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Zhejiang Hisun Pharmaceutical Co (SHSE:600267), the current FCF Margin % is 13.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.72 is trading 32.4% above its estimated GF Value™ of ¥8.85.
GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:600267:
FCF Margin %: 13.52% (52% above median its 10-year median of 8.87)
GF Value™: ¥8.85 vs. price of ¥11.72 (32.4% above fair value)
Industry Position: 426.1% above the Drug Manufacturers median (#142 of 963)
No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Hisun Pharmaceutical Co Business Description
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
58GF Score
Get the complete analysis for SHSE:600267
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600267 has been successfully added to your 
